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Abstract 
Background: 
Diabetic retinopathy, the leading cause of blindness among people aged 20 to 65 years in 
developed countries, is also a major sight threatening complication of Diabetes Mellitus in 
the developing world. It is estimated that almost all diabetics eventually suffer from any form 
of Diabetic Retinopathy. Pakistan, a developing nation, has a high burden of Diabetes with a 
prevalence of 6.7% and has nonetheless a high presence of Diabetic Retinopathy which is 
responsible for 0.5% of all acquired blindness in the country. Previous studies from the 
country report the frequency of Diabetic Retinopathy as high as 55%. However, none of these 
studies used fundus camera for the detection of Diabetic Retinopathy which is the gold 
standard procedure. 
Objectives: 
To study the frequency of Diabetic Retinopathy and Diabetic Macular Edema in Type 1 & 
Type 2 Diabetes Mellitus patients using fundus photography and factors associated with them 
in a tertiary care hospital in Karachi, Pakistan 
Methods: 
A retrospective cross-sectional analysis of diabetic patients’ records undergoing fundus 
photography between May 2010 & December 2013 at Dow University Hospital was done. 
A total of 1167 diabetic patients were identified for the study. Data was retrieved from 
hospital records using Medical Record numbers of patients who underwent fundus 
photography. Patients were identified as having (1) No Diabetic Retinopathy (No DR), (2) 
Mild Non-Proliferative Diabetic Retinopathy (Mild NPDR), (3) Moderate Non-Proliferative 
Diabetic Retinopathy (Moderate NPDR), (4) Severe Non-Proliferative Diabetic Retinopathy 
(Severe NPDR) or (5) Proliferative Diabetic Retinopathy (PDR). Presence of Diabetic 
Macular Edema was identified separately as (6) retinopathy patients without Diabetic 
Macular Edema (No DME), (7) patients with Diabetic Macular Edema but no Clinically 
Significant Macular Edema (DME only) and (8) patients with Clinically Significant Macular 
Edema (CSME). 
Statistical analyses were performed using IBM SPSS v 20 for Windows. The records revealed 
36% cases with missing data in 20 variables. The data was missing at random therefore 
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Multiple Imputations was employed to handle missing values. The variables retained their 
characteristics and there was no statistically significant difference in the mean values of all 20 
variables before and after multiple imputations. Therefore, we used all 1167 patients’ data for 
analyses (using pooled values after multiple imputations). Means and corresponding 95% 
confidence intervals were calculated for continuous variables while frequencies and 
percentages were computed for categorical variables. One-Way ANOVA and Pearson’s Chi-
Squared test were used to identify statistically significant difference in these variables for all 
categories of retinopathy. Binary Logistic Regression was employed to calculate Crude and 
Adjusted Odds Ratios with 95% confidence intervals for the factors associated with Diabetic 
Retinopathy and Diabetic Macular Edema. 
Results: 
A total of 853(73.1%) were found to have Diabetic Retinopathy with Mild Non Proliferative 
Diabetic Retinopathy in 395 (34%), Moderate Non Proliferative Diabetic Retinopathy in 321 
(27.5%), Severe Non Proliferative Diabetic Retinopathy in 45 (3.9%) and Proliferative 
Diabetic Retinopathy in 92 (7.9%) patients. Diabetic Macular Edema was present in 214 
(25.1%) of these 853 patients while Clinically Significant Macular Edema was present in 130 
(15.2%). Ninety two (11%) patients had Clinically Significant Macular Edema in both eyes. 
Univariate analyses using Binary Logistic Regression revealed that Fasting Blood Glucose, 
Random Blood Glucose, Glycosylated Hemoglobin, Duration of Diabetes Mellitus, presence 
of Hypertension,  Bod Mass Index, Urinary Micro Albumin excretion Waist Circumference 
and Waist-Hip Ratio were positively associated with any form of Retinopathy in diabetics, 
whereas High Density Lipoprotein levels were negatively associated with Diabetic 
Retinopathy. However, on multivariable analyses, only Fasting Blood Glucose, Glycosylated 
Hemoglobin, Duration of Diabetes, presence of hypertension, High Density Lipoprotein 
levels and Urinary Micro Albumin excretion retained their statistically significant 
associations. 
For Diabetic Macular Edema, Univariate analyses showed Glycosylated Hemoglobin, 
presence of Hypertension and Lower levels of High Density Lipoprotein levels were 
significantly associated. However, in multivariable model, only HbA1c and presence of 
Hypertension retained their statistically significant association with Diabetic Macular Edema.  
13 
 
Conclusion: 
Prolonged hyperglycemia, lower levels of High Density Lipoproteins and Urinary 
Microalbumin excretion are associated with Diabetic Retinopathy. Whereas, progression of 
Diabetic Macular Edema is associated with hyperglycemia and presence of Hypertension. 
Key Words: 
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema, Clinically Significant 
Macular Edema 
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Chapter 1: Introduction 
1.1 BACKGROUND 
1.1.1 Diabetes Mellitus & its complications; the Dreaded Pandemic:  
The turn of the 21st century saw the drastic increase in the prevalence of Diabetes Mellitus 
(DM), mainly type 2. In the year 2000, the global prevalence of Diabetes Mellitus (both type 
I &II) was estimated to be 2.8%, however, based on the reported data and trends from around 
the world, it is estimated that 4.4% of the world’s population will have Diabetes Mellitus in 
the year 2030.[1] This projected  increase in the prevalence means there will be 195 million 
new cases of Diabetes Mellitus in just 30 years (increasing from 171 Million diabetics in 
2000 to 366 Million in 2030). These new cases are more than the total number of Diabetics in 
the year 2000 alone. The tragedy doesn’t end here; the epidemiologic transition through 
which most of the developing countries are going through means that majority of the burden 
of diabetics will be in these countries. According to the International Diabetes Federation 
(IDF), by the year 2030, 9 of the top 10 countries with highest projected Diabetes burden will 
include nations like China, India, Brazil, Bangladesh, Mexico, Rusian Federation, Egypt and 
Pakistan. These nine countries (tenth being USA) are developing economies and will bear 
333.6 Million of 366 Million cases of Diabetes Mellitus in 2030.[2] These projections 
implicate that about 91% of the world’s Diabetes burden will be in aforementioned 9 
developing countries by 2030. These projections are nothing but horrifying.  
Much of the burden of DM on healthcare systems is attributed to the complications associated 
with it. This is evident by the fact that in 2007 the global health expenditure on preventing 
and treating Diabetes and its complications was 232 Billion US Dollars. This is projected to 
exceed 302 Billion USD by year 2025.[3] Tragic enough, just 20% of this money is spent on 
diabetics in the low and middle income countries where more than 80 percent of the diabetics 
live. For comparison, in 2010, annual expenditure for Diabetes patients in the USA was 7,383 
USD per patient, while this reduced to just 24 USD per patient when it comes to Pakistan.  
The monetary burden of DM complications can be imagined by the fact that the health 
expenditure is three times higher on patients with macro vascular complications with type 2 
DM than those without complications.  
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With increased longevity of patients with DM and increasing prevalence, the complication of 
diabetes mellitus pose a great threat to the overall health situation in the world. Although, 
better appreciation of the risk factors and early detection of the complications have lowered 
the burden of these complications in developed countries but this is unfortunately not true for 
the developing countries where sub optimal care and lack of proper implementation of 
screening protocols is adding up to the burden of DM complications. [4] 
Although, Cardiovascular disease (CVD) is the leading macrovascular complication of 
T2DM and approximately half of the patients with T2DM die of cardiovascular causes, the 
microvascular complications are the major cause of social and financial burden of Diabetes. 
[5] These complications include Retinopathy, Nephropathy, Neuropathy and small vessel 
vasculopathy causing lower limb amputation.  
1.1.2 Diabetic Retinopathy; the earliest complication:  
Diabetic Retinopathy (DR) is the earliest and often underestimated complication of Diabetes 
Mellitus. It is a chronic progressive, sight threatening complication of DM affecting the 
retinal microvasculature associated with prolonged hyperglycemia. The importance of DR 
can be estimated by the fact that the knowledge of the cutoffs of plasma glucose levels for 
diagnosing diabetes mellitus are based on two sets of information and Plasma Glucose Level 
associated with Retinopathy is one of them.   
Global estimates report that, around 34.6% of all diabetics suffer from any form of 
retinopathy, and it is the leading cause of acquired blindness among adults of working age in 
industrialized countries [6, 7]. Globally, it accounts for 5% of all cases of blindness. [8] This 
situation becomes worse when it comes to non-industrialized countries where screening 
protocols are not strictly observed.  
1.1.3 Pathophysiology &Natural history of Diabetic Retinopathy 
The natural history of diabetic retinopathy is affected by the effect of increased bllod glucose 
due to DM on the retinal capillaries. It progresses from Non-Proliferative form, characterized 
by increased vascular permeability causing few microaneurysms  in Mild NPDR to more 
microaneurysms and blot haemorrhages in Moderate NPDR to venous beading in Severe 
form causing vascular closure. As a consequence new but abnormal & fragile blood vessels 
are formed on the retina and posterior surface of Vitreous.  
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Diabetic Macular Edema (DME), which is the thickening of the macula due to more 
permeable vessels, affecting central vision can develop at any stage of DR. it is sometimes 
described as a complication of Diabetic Retinopathy.[9] Clinically Significant Macular 
Edema (CSME) is the more severe form requiring immediate intervention.  
1.1.4 Diagnosis & Classification:  
According to the Early Treatment Diabetic Retinopathy Study (ETDRS) the gold standard for 
detecting Diabetic Retinopathy consists of 30-degree stereoscopic photography of seven 
standard fields on color film. [10] ETDRS is in turn a modification of Diabetic Retinopathy 
Study (DRS) [11] and the original Airlie House Classification. [10] This classification is used 
as a full disease classification and it is not for population based screening.  
The classification of DR is based on the presence or absence of abnormal new vessels as 
Proliferative Diabetic Retinopathy (PDR) or Non- Proliferative Diabetic Retinopathy 
(NPDR) respectively. Non-Proliferaive DR is further divided into Mild, Moderate & Severe 
forms based on the number of microaneurysms seen on fundoscopy.  
Diabetic Retinopathy affecting the Macula lutea, area responsible for central vision, is 
separately defined as Diabetic Maculopathy. ETDRS defined Clinically Significant Macular 
Edema (CSME) as retinal thickening and/or hard exudates within 500 µm of the fovea, or 
when there is a zone of edema that is larger than the papilla at a distance of one papillary 
diameter. [12]  CSME is a serious condition requiring urgent intervention as it can be present 
while the patient can still see well however the vision is acutely endangered by the 
retinopathy. Another aspect of Diabetic Maculopathy is ischemic in which capillary network 
is occluded and confers a poor prognosis for visual acuity as this condition is still not 
treatable. [13] Diabetic Maculopathy can also present as the combination of both edematous 
and ischemic types.  
1.1.5 Delay in diagnosis & ScreeningProtocols:  
Current screening protocols recommend that T1DM patients should be examined by 
ophthalmologist for dilated eye examination within 5 years of diagnosis. [14] However, 
studies suggest that some proportion of T2DM patients had already developed DR when they 
are diagnosed therefore these patients should have an initial dilated eye examination at the 
time of their diagnosis of diabetes. 
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However, this is not in practice in the developing parts of the world. For example a study [15] 
from Pakistan showed that 15% of T2DM patients had already developed some form of 
Retinopathy when they were first diagnosed with Diabetes. similarly, Mahar PS and 
associates report that om their community based study, 2.18% of newly diagnosed T2DM 
patients had retinopathy. [16] 
Looker HC et al [17] reported that 19.3 % of patients were found to have any form of 
retinopathy immediately after diagnosis of T2DM. Similarly a study from Inida reports that 
5% of newly diagnosed diabetics had DR. [18] The UKPDS reports that retinopathy was 
present at the time of diagnosis of T2DM in 39% of men and 35% of women.[19] 
Where these study points towards the delay in diagnosis of T2DM, the use of direct 
ophthalmoscopy to detect DR raises the question that whether its an underestimation of the 
true burden. The gold standard to detect DR is Indirect Ophthalmoscopy using Fundus 
Camera. [10] Despite this, very few studies used indirect fundusphotography to diagnose DR 
due to its high cost. 
1.2 EPIDEMIOLOGY OF DIABETIC RETINOPATHY 
1.2.1 Global Burden: 
In many countries Diabetic retinopathy is the commonest cause of preventable blindness 
among individuals of working age group. In the US, the prevalence of DR is reported as high 
as 28% while that of Diabetic Macular Edema as 3%. [20] In other developed countries the 
tally is similar, ranging between 17 & 45% for DR while that for DME between 3 & 13%. 
[21, 22] However, a recent meta-analysis considering studies between 1980 to 2008 reports 
that the overall all risk of any form of DR is 35% while that of PDR is 7.2% and for DME, 
7.5%. [23]  
1.2.2 Diabetic Retinopathy in South Asia 
Recently, Asia has emerged as a major Diabetes burden bearer in the world. Countries like 
China, India, Bangladesh and Pakistan have, not only high prevalence of Diabetes, but also of 
its complications.  
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Though DR is not the main cause of blindness, nonetheless its prevalence is far more than 
that in the developed world. The poor control of diabetes and lifestyle related risk factors in 
these countries pose a great threat.  
Literature published from China report that DR is present in 37 to 43% of diabetics while 
DME is present in 2.6 to 3.5% of these patients. [24, 25] Studies from India report the 
prevalence to be ranging between 17.6% & 28.2% . [18, 26] similarly,  While Ahmed KR 
[27] reports that in Bangladesh  50.6% of diabetics develop DR within 15 years of onset of 
DM. 
1.2.3. Situation in Pakistan 
With a national diabetic prevalence of 6.7%, Pakistan is one of the high burden countries. [2] 
However, there have been no nationwide survey of the complications attributed to diabetes 
mellitus. Many small studies, differing in study settings and methods have reported a great 
deal of variation in the prevalence of DR in the country. A population based screening study 
in subjects over 30 years reported that DR was seen in 27.43% of Diabetics. [16] Similarly, 
another community based screening study reported DR to be present in 15.7% of the 
diabetics. However a hospital based study from Quetta city reports the frequency of DR to be 
54.6%. [28] 
Another considerable issue with past studies is the usage of non-uniform diagnosing tools for 
DR. to the best of of our knowledge, no study used fundus camera for the indentification of 
DR which is the gold standard. [12] 
1.3 FACTORS ASSOIATED WITH DIABETIC RETINOPATHY 
Many studies have been carried out to acquire an in-depth understanding of the factors 
associated with Diabetic Retinopathy. The most prominent of these are the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR). This study started in 1979 was 
aimed to describe the frequency and incidence of diabetic complications. The study resulted 
in more than 210 reports adding great to the present knowledge of DR. [29-33] A clinical trial 
run between 1977 & 1997, the United Kingdom Prospective Diabetes Study (UKPDS) and its 
post trial studies helped further in understanding Diabetic Retinopathy and other 
complications of Diabetes Mellitus. [34-37] 
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1.3.1 Blood Glucose Levels/HbA1c: 
Hyperglycemia is by far the most important factor associated with diabetic retinopathy. High 
blood glucose level is the key factor in the pathogenesis of DR in many ways. During the last 
decade of 20th century and the first decade of 21st century a number o studies and trials gave a 
greater understanding of how high blood glucose levels caused the microvascular 
complications of Diabetes Mellitus. [38-41] Sparing the complex bio-chemical mechanism in 
production of Reactive Oxygen Species (ROS), it is now clear that high blood glucose levels 
adversely affects the functional retinal vasculature causing impaired retinal blood flow, 
leakage of capillaries, increased leaukocyte & monocyte adhesion and capillary closure 
causing localized hypoxia (leading to neovascularization in PDR).   
Long standing high glucose levels are associated with the worse forms of DR. Although the 
easiest way to measure blood glucose is the Random (Post Prandial) and Fasting Glucose 
levels espeicaially after the introduction of portable glucose monitoring devices, however, the 
better picture is given by the glycosylated hemoglobin or the HbA1c. The Wisconsin 
Epidemiologic Study of Diabetic Retinopathy showed that the relative risk of developing 
Proliferative Diabetic Retinopathy increases to 2.64 (95% CI, 2.18-3.20) times when the 
HbA1c is between 12.1 to 19.5% and chances of developing Macular Edema is 3.37 times 
(95% CI, 2.12-5.34).[30] Lauritzen T et al showed in a study among T1DM patients that near 
normal glucose levels over a period of 1 year (maintained by Insulin) significantly stopped 
the progression of DR. [42] Many studies around the World have shown the association of 
HbA1c with the progression of DR with Odds Ratio ranging from 1.38-4.53. [43-50] 
FBG: Komamoto study reports that based on insulin treatment among typoe 2 diabetics, the 
threshold of FBG for onset and progression of microvascular complications of diabetes such 
as Retinopathy is <6.0 mmol/L (110mg/dL). That of HbA1c is <6.5% and that of 2h 
postprandial blood glucose is <9.9mmol/L (<180 mg/dl).[51] 
Another trial, the DCCT [52, 53] demonstrated that the risk of progression of DR can be 
reduced by 54% and development of Severe NPDR or PDR can be reduced by 47% by 
intense blood glucose control. Similarly, the trial also reported that the need for laser surgery 
can be reduced by 56% and the risk of DME can be reduced by 23%. 
RBG  
20 
 
1.3.2 Hypertension: 
The epidemiological association between DR and Hypertension has long been known. The 
effect of elevated blood pressure on ratina is evident from Hypertensive Retinopathy. 
However, HTN is not just a risk marker for DR. The combination of HTN and 
uncontrolledblood glucose levels has been shown to increase the risk of DR many fold. 
(REF) UKPDS showed that good control of blood pressure can reduce the risk of 
development as well as progression of diabetic eye complications. [34, 54] 
Systemic hypertension further worsens the already impaired retinal due to hyperglycemia 
causing by susceptibility to capillaries. However, blood pressure levels are associated with 
the progression of retinopathy in diabetics even in the absence of systemic hypertension. A 
study among T1DM patients showed that even within normal range, higher blood pressure 
levels are associated with the progression of retinopathy. [55] 
1.3.3 Duration of DM: 
The duration of Diabetes Melitus has been shown to be associated with both the incidence of 
DR and also the progression of it. It might not be an independent risk factor for DR since 
longer exposure to hyperglycemia and other factors might be the main causing factors behind. 
Nevertheless, duration of DM is reported to be positively associated with the incidence and 
progression of DR in both types of DM by majority of researchers. [32, 50, 56, 57] 
1.3.5 Urinary Micro Albumin: 
The association of overt albuminuria, with micro and macro vascular complication of 
diabetes mellitus has been known for quite some time. However, microalbuminuria has now 
been reported as independently associated with the presence of diabetic retinopathy in several 
studies. [58-60] The Wisconsin Epidemiologic Study of Diabetic Retinopathy showed that 
Microalbuminuria can be used as a marker for the risk of PDR. [59] Suvage S et al [58] in 
their study on T2DM patients found that Urinary Albmin Excretion was not only positively 
associated with DR but with Neuropathy & Cardiovascular Diseases as well. Similar study 
from China [45] also found out that 24hour urinary albumin excretion was greater in those 
diabetic who had developed retinopathy. 
However, a cross sectional study on Australian T2DM patients reported however that urinary 
albumin to creatnine ratio was significantly higher in those with DR. [44] 
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1.3.6 Serum Cholesterol: 
Several studies have pointed towards the association of serum cholesterols with diabetic 
retinopathy. In Early Treatment Diabetic Retinopathy Study, the authors showed a 
relationship of total cholesterol & LDL with hard retinal exudates. [61] Klein BEK et al  
showed in the Wisconsin Epidemiologic Study of Diabetic Retinopathy that the ratio of total 
to HDL cholesterol was positively associated with the progression of diabetic retinopathy. 
[62] 
1.3.7 Type of Diabetes Mellitus: 
 Possibly due to early onset of type 1 diabetes mellitus, retinopathy is usually seen earlier and 
more in these patients. According to Fong DS et al [63], all patients with type 2 DM suffer 
from DR within first twenty years of the onset of DM while over 60% of T2DM patients 
suffer with DR during this time. This might be due to relatively aggressive need of glycemic 
control in T1DM patients which is not always obtained. However, sight-threatening 
retinopathy in these patients is rare before puberty. WESDR [32] findings support the 
aggressive progression of DR in T1DM patients as they reported the prevalence of DR after 5 
years of diagnosis as 17% while this was raised to 97.5% when they have had T1DM for 15 
years or more. Moreover, though progression of DR is slower in T2DM, almost all patients 
suffer from some degree of DR in their life. 
1.3.8 Age: 
Age has a unique association with the incidence & prevalence of DiabeticRetinopathy. 
WESDR reports that the risk of DR increases 3.2 times for post-menarchal T1DM patients. 
[64] Espeially in the case of Proliferative DR, pre-pubertal age seems to attribute a protective 
effect. Though not clearly understood, many factors have been suspected to play a role in this 
association like increased growth hormone, increased insulin growth factor, poorer glycemic 
control and increased sex hormones like testosterone. Another study reports that the odds of 
having Daibetic retinopathy is raised to 6.1 times when comparing pre & post-pubescent 
patients. [65] WESDR however reports that in the T2DM patients, the age had no or very 
little effect  on the incidence of retinopathy and no patient older that 80 years of age was 
found to develop proliferative DR. [64] 
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However, Holl RW and associates [66] are of the opinion that the apparent lack of 
microvascular complications especially Retinopathy in children (prepubescent) is due to the 
lack of routine diagnosis of these complications in the diabetic children.  
1.3.9 Smoking: 
Some researchers have reported smoking to be positively associated with the progression of 
DR among diabetic patients. [67-70]it is reported that cigarette smoking increases the risk of 
diabetic complication probably by increasing insulin resistance. [70]smoking has been shown 
to increase the risk of microvascular complications among T1DM patients to a greater extent 
while macrovascular complications in T2DM patients.  
UKPDS 50[37] however reports that not smoking was positively associated with both DR 
development and progression. The authors of this study suspects the possible pharmacologic 
effects of nicotine to be responsible for this inverse association. 
1.3.10 Insulin Use:  
Since intensive glycemic control by Insulin Treatment has shown to delay or event prevent 
the progression of diabetic retinopathy Therefore Serum Insulin level is inversely propotional 
to the severity of DR especially in T2DM patients. [19, 71] In T1DM patients, WESDR 
reports that better glycemic control using better dosing of insulin proves to be a protective 
factor against DR incidence & progression. These findings are also similar to those found by 
other study groups like the Krov Collabortaion Study Group.[72]  The Komamoto Eye Study 
in T2DM patients reported that group of patients receiving multiple insulin injections to 
attain better glycemic control had less cumulative worsening of Retinopathy compared to the 
group receiving conventional insulin injection therapy. [51] 
 However, The Los Angeles Latino Eye Study reports that being on insulin treatment has 
greater Odds of having DR (OR 3.2). [57] 
1.3.11 Anthropometry: 
Anthropometry has been indicated in several studies for  risk factor assessment for DR.  
Dirani M et al reported in their study that higher BMI is associated with risk of any form of 
DR aming type 2 DM patients and that Obese people hve 6.5 times more risk of having DR. 
the authors also reports that Neck circumference and waist circumference are also associated 
with any form of dr while BMI and neck circumference were positively associated with the 
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progression of DR.[73] Similary, a recent study from Croatia, reported that, besides other 
factors, higher BMI was positively associated with the progression of DR. [74] especially in 
Asian population, BMI has been frequently reported in studies to be associated with DR. [75, 
76] 
EURODIAB study explained that waist-hip ratio and fasting triglyceride levels which are 
markers of Insulin Resistance are positively associated with DR amiong type 1 DM 
patients.[60] 
 
1.4 PROBLEM STATEMENT:  
There is considerable variation in the prevalence of DR reported in the studies from Pakistan. 
In addition, the methods to detect DR in diabetic patients used in these studies are not 
uniform. To the best of our knowledge, no study from the country used fundus photography 
to identify DR. instead, direct ophthalmoscopy was used which is very much operator 
dependant hence, an underestimation of the problem can be suspected.  
1.5 PRESENT STUDY: 
Present study was designed to study the frequency of retinopathy including macular edema in 
diabetic patients using fundus photography, which is the gold standard tool for the detection 
of DR. There is evidence that use of Fundus Camera to diagnose and detect grading of 
Diabetic Retinopathy can significantly detect more cases of diabetic retinopathy especially 
milder forms then direct fundoscopy. [10, 77] This study used Topcon TRC.50EX® retinal 
camera with Nikon D5000® 12.3 megapixel digital camera for detection of DR I diabetic 
patients. This study also looked into the factors associated with Diabetic Retinopathy and 
Diabetic Macular Edema.    
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1.5 Objectives 
General Objective:  
To study the frequency of Diabetic Retinopathies using fundus photography and factors 
associated with them among patients with Diabetes Mellitus in a tertiary care hospital in 
Karachi, Pakistan 
Specific Objectives: 
1. To find out the frequency of Diabetic Retinopathy among type1 and type2 diabetes 
mellitus patients  
2. To find out the frequency of Diabetic Macular Edema among type1 & type2 diabetes 
mellitus patients  
3. To study the factors associated with Diabetic Retinopathy among type 1 & type 2 
diabetes mellitus patients 
4. To study the factors associated with Diabetic Macular Edema among type 1 & type 2 
diabetes mellitus patients 
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Chapter 2: Patients & Methods 
2.1 Research Design: 
Cross Sectional; A retrospective analysis of hospital records were done on diabetic patients 
who underwent fundus photography. 
2.2 Study Setting:  
Department of Ophthalmology & National Institute of Diabetes & Endocrinology, Dow 
University Hospital. Dow University Hospital is a large, government run, tertiary care 
hospital in Karachi, the largest city of Pakistan (with a population of over 20 Million). The 
hospital has a total monthly patient turn over of around 100,000 patients. Department of 
Ophthalmology & National Institute of Diabetes & Endocrinology combined, however have a 
monthly patients turnover of approximately 40,000 patients. 
2.3 Duration of Study:  
August 2013 to December 2013 
2.4 Sample Size:  
Using OpenEpi sample size calculator, keeping the frequency of Diabetic Retinopathy among 
T2DM patients in Karachi as 27.43% as reported by Mahar PS et al [16], and Confidence 
Level at 95%, the sample size was calculated to be 157 at maximum error of ± 7% with 
estimate.  
Sample size was calculated using the proportion of DR among T2DM patients which yielded 
larger sample size compared to that calculated with T1DM reported by WESDR [30](n=95). 
Therefore, larger sample size was considered for this study 
2.5 Sample Selection 
Data records for all the patients who had gone through fundus photography and were 
previously diagnosed as having Diabetes Mellitus of either type were taken into the study. 
Figure 1 shows the procedure of sample selection. 
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Figure 1 Selection of study subjects from Department of Ophthalmology, Dow University Hospital 
 
2.6 Operational Definitions  
1. Diabetic Retinopathy: 
Diabetic Retinopathy was identified on the basis of history of Diabetes Mellitus (both type 1 
& 2) and findings of fundus photography using Topcon TRC.50EX® retinal camera with 
Nikon D5000® 12.3 megapixel digital camera as follows: [78] 
2. Non-Proliferative Diabetic Retinopathy (NPDR):  
NPDR was diagnosed and graded by the presence of microaneurysm without any formation 
of abnormal new blood vessels. 
(i) Mild NPDR: Atleast one of the following: 
a) Microaneurysms 
b) Dot/blot hemorrhages  
(ii) Moderate NPDR: Marked Hemorrhages, Cotton Wool spots, Venous Beeding 
(VB), Intra Retinal Microvasculature Abnormalities (IRMA) to mild degree 
(iii) Severe NPDR: Marked Hemorrhages in all four quadrants, Venous Bleeding (VB) 
in 2 or more quadrants, Marked Intra Retinal Microvasculature Abnormalities 
(IRMA) in one quadrant 
Patients 
selected for the 
Study 
Selection of 
Diabetic 
Patients 
Fundus 
Photography 
Record 
2432 
patients 
1167 
Patients with 
Diabetes Mellitus 
853 patients with 
Retinopathy 
314 patients 
without 
Retinopathy 1265 
Patients without 
Diabetes Mellitus 
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3. Proliferative Diabetic Retinopathy (PDR):  
Proliferative Diabetic retinopathy was diagnosed by the presence of abnormal new blood 
vessels on or around the optic disc. 
4. Diabetic Macular Edema: 
Retinal thickening within 2 disc diameters of the center of the macula, resulting from the 
leakage of plasma constituents into the surrounding retina. 
5. Clinically Significant Macular Edema (CSME):  
CSME was identified when one of the following was present:  
a) Retinal thickening at or within 500 microns or 1/3 disc diameter of center of macula.  
b) Hard exudates at or within 500 microns of the center of the macula with adjacent 
retinal thickening.  
c) Retinal thickening GREATER than 1 disc diameter in size which is within 1 disc 
diameter from the center of the macula  
6. Grading of Diabetic Retinopathy:  
In case the findings in both eyes of the same patient differed, the patient was graded 
according to more severe form as per Early Treatment Diabetic Retinopathy Study. [10] 
7. Type of Diabetes:  
Type of Diabetes Mellitus was identified from the medical records. These patients were 
already diagnosed as having either type 1 or 2 DM at NIDE.  
2.7 Methods:   
A Retrospective cross-sectional analyses was performed for the identification of patients 
suffering from Diabetic Retinopathy. From May 2010 (when the facilty of Fundus 
Photography was initiated at the department) till December 2013, Two thousand four hundred 
and thirty two patients underwent Fundus Photography for both Anterior & Posterior 
chambers of the eye after pupil dilatation using 1% tropicamide Eye drops. Topcon 
TRC.50EX® retinal camera with Nikon D5000® 12.3 megapixel digital camera was used for 
fundus photography for both eyes during this period.  
Of these 2432, 1167 were suffering from Diabetes Mellitus (either type I or II). File records 
were accessed using medical record numbers of these patients present in the records of 
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fundus photographs and information on the variables were collected. For Patients with more 
than one retinal photographs (on different dates) the earliest one was considered. 
Selection of Variables: 
For a total of 1167 diabetic patients, variables were selected for sociodemographic, clinical 
and biochemical characteristics. The list of the variables is as follows: 
Age, Gender, Education, Marital Status, Family History of Diabetes, Type of Diabetes, 
Smoking Status, Duration of Diabetes, Height, Weight, Systolic Blood Pressure, Diastolic 
Blood Pressure, Hip circumference, Waist circumference, Type of Medication for Diabetes 
Mellitus 
Random Blood Glucose (RBG), Fasting Blood Glucose (FBG), Glycosylated Hemoglobin 
(HbA1c), Urea, Creatinine, Sodium, Potasium, Bicarbonate, Total Cholesterol, Total 
Triglycerides, High Density Lipids, Low Density Lipids, Urinary Microalbumin,  
Data Collection tools: 
All biochemical parameters and anthropometric measurements were collected in Dow Lab 
(DUH) and NIDE respectvely. Height was measured as standing height using standard height 
scale for adults at NIDE. Weight of the patients were recorded using analogue weighing scale. 
Blood Pressure readings were measured using mercurial sphygmomanometer. Waist 
circumference was measured using standard cm/inch tape at midway between bottom of ribs 
& top of hip bone. Similarly, Hip circumference was measured at the widest point. Lipid 
profile, was assessed by enzymatic calorimetric test. Fasting and random blood glucose was 
estimated using the automatic biochemical analyzer (Hitachi 902) which uses the photometric 
technique of glucose estimation at DOWLAB. HbA1c was analyzed using  automated 
analyser (Sysmex). Urinary Micro Albuminuria was determined by using semi-quantitavie 
dry immunological screening strip. 
Ethical considerations: 
The study was approved by Regional Committee for Medical and Health Research Ethics 
(REK) Norway and Institutional Review Board (IRB) Dow University of Health Sciences, 
Karachi, Pakistan. 
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Statistical Analyses:  
Statistical analyses were performed using IBM SPSS v 20 for Windows (SPSS Inc. Chicago, 
Illinois). 
Handling of Missing Data; Multiple Imputations:   
Missing data identification analyses was done on 20 variables to identify at least 0.01% of 
data missing to be selected for Multiple Imputation using IBM SPSS v 20 for Windows 
(SPSS Inc. Chicago, Illinois). The analyses yielded that 90% values were found missing 
while only 745 (63.83%) of the cases were complete. The percentages of missing data for all 
20 variables are shown in Figures 2 & 3 and Table 1 shows the pattern of missing data. The 
missing data pattern showed that the data was “Missing at Random” (Figure 3 showing 
isolated islands of missing data suggesting the ‘missing at random pattern’) therefore Markov 
Chain Monte Carlo method was used to impute the missing data. A total of five iterations 
were done to generate the pooled results for the missing values. 
After Multiple Imputations for missing variables, the values with their mean and standard 
deviations alongwith their comparison with non-imputed data (analyses including missing 
values) are shown in Table 2.  There was no statistically significant difference observed in the 
values before MI & Pooled Values after MI. Therefore all descriptive results for 1167 
patients are shown using pooled values (after MI). 
Figure 2 Percentages of missing data according to Variables, Cases and Values for all patients (n=1167) 
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Figure 3 Missing values pattern showing data ‘missing at random’ for 18 selected variables of all patients (n=1167) 
 
Table 1 The variables and corresponding percentages of missing data (in order of highest missing percentage first) 
S. No. Variable  Valid Values  Missing 
  1 Urinary Micro Albumin  512 56 
2 Urea  591 49  
3 Creatinine  598 49  
4 Sodium 598 49  
5 Potassium  598 49  
6 Bicarbonate  598 49  
7 Total Serum Cholesterol  598 49  
8 Triglycerides  689 41  
9 HDL  689 41  
10 LDL  689 41  
11 HbA1c  712 39  
12 FBG  751 35  
13 Waist Circumference  751 35  
14 Hip Circumference  765 35  
15 RBG  872 25  
16 Duration of Diabetes  1089 7  
17 Weight  1121 4  
18 Height  1121 4  
19 BP Systole  1160 1  
20 BP Diastole  1160 1  
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Table 2 Comparison of Imputed & Non-Imputed Data (n=1167) 
 Mean (SD) Before MI  Pooled Mean after MI  P-value  
FBG mmol/L 9.89 (3.97)  9.86 (4.03)  0.881 
RBG mmol/L 13.38 (4.97)  13.38(5.09) 0.993 
HbA1c % 9.6 3 (3.39)  9.63 (3.39) 0.999  
Duration of Diabetes years  15.08 (7.43)  15.08 (7.43) 0.999  
Total Serum Cholesterol mmol/L  4.78 (1.25)  4.85 (1.28) 0.243 
Total Triglyceride mmol/L 1.98(1.05)  1.97 (1.06) 0.861 
HDL mmol/L 1.04 (0.40)  1.05 (0.41) 0.832 
LDL mmol/L 2.88 (0.94)  2.88 (0.98) 0.829 
Urea mmol/L 9.89 (4.96)  9.71 (5.01) 0.313 
Creatinine µmol/L 85.75 (75.14)  84.86(74.25)  0.860 
Sodium mmol/L 139.99 (5.64)  140.01 (5.83) 0.670 
Potassium mmol/L 4.76 (0.4)  4.75 (0.5) 0.771 
Bicarbonate mmol/L 24.23 (4.2)  24.13 (4.2) 0.607 
Urine Micro Albumin µg/min 66.92 (88.22)  70.81 (90.91) 0.446 
Weight Kg 69.47 (14.01)  69.45 (14.05) 0.960 
Height m 1.61 (0.10)  1.61 (0.11) 0.898 
BP Systole mmHg  127.45 (19.09)  127.58 (19.17) 0.869 
BP Diastole mmHg 80.27 (9.74)  80.23 (9.78) 0.934 
Waist cm 100.08 (11.69)  99.99 (11.69) 0.869 
Hip cm 103.95 (10.25)  103.65 (10.24)  0.541 
 
Descriptive Statistics: 
The data on all 1167 patients after Multiple Imputation for missing values and descriptive 
results were generated. Frequencies and percentages of Diabetic Retinopathy, Diabetic 
Macular Edema & Clinically Significant Macular Edema was calculated. Mean and 95% CI 
for continuous variables like bio-chemical values were calculated. Similarly, frequencies and 
percentages of categorical variables were computed.  
Inferential Statistics: 
T-Test & One Way ANOVA was employed to see the difference between continuous 
variables of patients with and without DR & DME. Tukey’s Post Hoc test was carried out to 
32 
 
identify statistically significant differences between different groups of DR. Variables with 
statistically significant difference (p-value <0.05) were included in Univariate analyses 
calculating Odds Ratios with 95% CI using Binary Logistic Regression. Variables 
maintaining their statistical significance were included in Multivariable analyses to calculate 
the adjusted Odds Ratios.   
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Chapter 3: Results 
From a total of 1167 diabetic patients who underwent fundus photography, 703 (60%) were 
male while 464 (40 %) were female. The mean age of the patients was 52.56 years (95% CI 
51.96- 53.17). Twenty nine (2.4%) of the patients had T1DM while 1138 (97.6%) patients 
had T2DM. 
3.1 Frequency of Diabetic Retinopathy and Diabetic Macular Edema 
A total of 853 (73.1%) of 1167 patients were found to have Diabetic Retinopathy. Frequency 
of different forms of Diabetic Retinopathy is as follows.  
Three hundred and ninety five (33.8%) patients were graded as having Mild NPDR, 321 
(27.5%) Moderate NPDR, 45 (3.9%) Severe NPDR whereas 92 (7.9%) were graded as 
having PDR. Figure 4 shows the proportions of different types of DR.  
A total of 214 (25.1%) of 853 were found to have Diabetic Macular Edema. Whereas, 
Clinically Significant Macular Edema (CSME) was found in 130 (15.2%) cases. Figure 5 
shows the proportion of DME & CSME in patients with DR. There were a total of 92 patients 
who had CSME in both eyes. 
Figure 4 Distribution of Diabetic Retinopathy according to severity 
 
DR: Diabetic Retinopathy, NPDR: Non-Proliferative Diabetic Retinopathy, PDR: Proliferative Diabetic Retinopathy 
27 % 
34 % 
27 % 
4 % 
8 % 
Proportion of different types of Diabetic 
Retinopathy ( n=1167) 
No DR
Mild NPDR
Moderate NPDR
Severe NPDR
PDR
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Figure 5 Distribution of Diabetic Macular Edema and Clinically Significant Macular Edema in Retinopathy patients 
 
DME: Diabetic Macular Edema, CSME: Clinically Significant Macular Edema 
 
In regards to type of diabetes, 25 of 29 (86.2%) patients with T1DM had Diabetic 
retinopathy. Whereas 828 of 1138 (72.8%) T2DM patients had any form of Diabetic 
Retinopathy. Figure 6 shows the distribution of different grading of Diabetic Retinopathy 
according to the type of DR.  
75 % 
10 % 
15 % 
Presence of Diabetic Macular Edema in 
patients with Retinopathy (n=853) 
Retinopathy without DME
DME without CSME
CSME
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Figure 6 Distribution of different forms of Diabetic Retinopathy according to type of Diabetes 
 
There were 7 T1DM patients with Diabetic Macular Edema (DME) while 207 with T2DM 
had macular edema. There was no statistically significant difference found in the presence of 
Diabetic Macular Edema according to the type of Diabetes. 
 
Figure 7 Distribution of Diabetic Macular Edema and Clinically Significant Macular Edema according to type of Diabetes 
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Diabetic Macular Edema and Clinically Significant Macular was found to be present in all 4 
grades of retinopathy, that is, mild, moderate and severe forms of Non Proliferative Diabetic 
Retinopathy and Proliferative Diabetic Retinopathy. The distribution of DME and CSME 
according to different grades of retinopathy is shown in Figure 8. 
Figure 8 Distribution of DIabetic Macular Edema and Clinnically Significant Macular Edema according to different grades 
of retinopathy 
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3.2 Sociodemographic characteristics 
The sociodemographic charactistics including Age, Gender, Marital status, Education, 
Smoking habit, and characteristics related to medical and family history are shown in tables 3 
and 4 for different grades of DR and DME respectively. 
Table 3 Sociodemographic and past medical and family hostory according to different grades of retinopathy (n=1167) 
  No DR  
n=314  
Mild 
NPDR  
N=395  
Moderate 
NPDR 
n=321  
Severe 
NPDR  
n=45  
PDR  
n=92  
Diabetes 
Type  
T1DM 
T2DM 
4 
310  
10 
385  
11 
310  
0 
45  
4 
88  
Gender  Male 
Female  
190 
124  
227 
168  
205 
116  
24 
21  
57 
35  
Age  <30 year 
>30 years 
16 
298 
9 
386 
10 
311 
0 
45 
4 
88 
Marital 
Status  
Ever Married 
Never Married  
298 
16 
388 
7  
313 
8 
45 
0  
90 
2  
Education  Illiterate 
Can Read 
Upto 5 years 
Middle (8 
years) 
Upto 10 Years 
Graduation 
Post 
Graduation  
54 
32 
52 
48 
42 
54 
29 
72 
57 
67 
59 
33 
71 
36 
54 
32 
55 
51 
43 
56 
30 
3 
4 
8 
11 
14 
5 
2 
7 
18 
10 
14 
23 
17 
3 
Smoking  Ever Smoked 
Never Smoked  
96 
218 
104 
291 
67 
254 
4 
41 
10 
82 
HTN Present 
Absent 
183 
131 
300 
95 
239 
85 
36 
9 
69 
23 
On Insulin 
Treatment  
Yes 
No  
26 
278  
32 
363  
31 
29  
2 
43 
14 
74  
Family 
History of 
DM  
Positive 
Negative 
Unknown  
162 
124 
28 
189 
183 
23  
195 
106 
20  
23 
19 
3  
46 
42 
4  
Family 
History of 
HTN  
Positive 
Negative 
Unknown  
116 
152 
46  
168 
137 
90  
169 
95 
57  
26 
11 
8  
46 
27 
19 
Family 
History of 
CVD  
Positive 
Negative 
Unknown  
103 
128 
83 
176 
122 
97  
155 
104 
62 
15 
27 
3  
24 
29 
39 
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Table 4 Sociodemographic and past medical and family history according to presence of Diabetic Macular Edema and 
Clinincallly SIgnificant Macular Edema 
  No  DME 
(only DR) 
N=639 
DME (without 
CSME) 
N= 84 
CSME 
N=130  
Diabetes 
Type  
T1DM 
T2DM 
18 
621 
4 
80 
3 
127 
Gender  Male  
Female 
349 
290 
48 
36 
122 
14 
Age  <30 year 
>30 years 
17 
622 
4 
80 
2 
128 
Marital 
Status  
Ever Married 
Never Married  
624 
15 
83 
1 
130 
0 
Education  Illiterate 
Can Read 
Upto 5 years 
Middle (8 years) 
Upto 10 Years 
Graduation 
Post Graduation  
78 
94 
103 
147 
110 
86 
21 
3 
11 
14 
18 
27 
6 
5 
55 
6 
23 
25 
3 
16 
2 
Smoking  Ever Smoked 
Never Smoked  
105 
534 
51 
33 
29 
101 
HTN Present 
Absent 
541 
98 
51 
33 
52 
78 
On Insulin 
Treatment  
Yes 
No  
41 
598 
15 
69 
23 
107 
Family 
History of 
DM  
Positive 
Negative 
Unknown  
340 
207 
92 
59 
18 
7 
64 
45 
21 
Family 
History of 
HTN  
Positive 
Negative 
Unknown  
312 
223 
104 
30 
36 
18 
67 
11 
52 
Family 
History of 
CVD  
Positive 
Negative 
Unknown  
224 
244 
171 
68 
12 
4 
78 
26 
26 
3.3 Biochemical characteristics 
The distribution of mean values with 95% CI of biochemical parameters according to 
different grades of diabetic retinopathy is shown in table 5. Similarly, mean values with 
corresponding 95% confidence intervals for these variables in 853 DR patients according to 
the presence of DME and CSME is shown in table 6. 
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Table 5 Biochemical parameters (Mean & 95% CI) according to different grades of retinopathy (n=1167) 
Mean (95% CI) No DR 
n=314 
Mild NPDR 
N=395  
Moderate NPDR 
n=321 
Severe NPDR 
n=45 
PDR 
n=92 
FBG  mmol/L 8.03 (7.70-8.37)  10.38 (9.94-10.82)  9.70 (9.10-10.31)  10.79 (9.71-11.86)  10.74 (9.64-11.83)  
RBG  mmol/L 11.68 (11.10-12.26)  14.72 (14.16- 15.28)  13.97 (13.35-14.60)  14.62 (13.14-16.16)  15.66 (14.68-16.63) 
HbA1c % 7.84 (7.55-8.13)  9.59 (9.38-9.80)  9.79 (9.56-10.03)  10.23 (9.70-10.76)  10.49 (10.07-10.91)  
DM Duration Years 4.39 (3.72-5.05)  13.29 (12.74-13.84)  17.99 (17.47-18.52)  19.26 (17.60-20.93)  17.89 (16.93-18.85)  
Age Years 51.41 (49.11-53.70)  51.38 (50.48-52.28)  50.11 (48.09-52.13)  53.29 (50.91-55.67)  53.76 (52.3-55.18)  
Urea mmol/L 10.26 (9.33-11.20)  9.58 (9.13-10.02)  9.98 (9.08-10.87)  11.43 (10.76-12.10)  11.64 (11.16-12.11)  
Creatinine µmol/L 82.21 (77.79-87.51)  54.80 (52.15-56.57)  78.67 (71.60-85.78)  90.16 (85.01-95.31)  114.03 (102.54-126.41)  
Sodium mmol/L 140.09 (139.00-141.19)  141.37 (140.69-142.04)  140.67 (139.91-141.44)  141.40 (139.64-143.15)  138.26 (136.26-140.21)  
Potassium mmol/L  4.84 (4.72-4.96)  4.50 (4.40-4.59)  4.70 (4.58-4.82)  4.74 (4.28-5.19)  4.15 (3.84-4.46)  
Chloride  mmol/L 103.93 (102.82-105.04)  101.35 (100.42-102.28)  100.65 (100.12-101.18)  104.40 (101.63-107.16)  102.28 (100.67-103.89)  
BiCarbonate  mmol/L 31.58 (26.78-36.37)  25.35 (24.80-25.90)  22.79 (22.00-23.57)  23.28 (20.89-25.66)  21.94 (20.30-23.58)  
Urine Micro 
Albumin  µg/min 30.30 (23.79-36.81)  80.53 (67.49-93.57)  87.63 (72.15-103.11)  93.11 (74.33-111.88)  96.89 (79.65-114.14) 
Height  m 1.63 (1.62-1.64)  1.60 (1.59-1.61)  1.62 (1.60-1.63)  1.57 (1.54-1.59)  1.66 (1.64-1.68)  
Weight  Kg  71.10 (69.02-73.18)  71.29 (69.96-72.62)  68.98 (67.30-70.66)  63.51 (59.74-67.28)  86.31 (82.85-89.77)  
BMI  Kg/m2 26.09 (25.62-26.57)  27.81 (27.32-28.30)  26.65 (26.13-27.17)  26.23 (24.89-27.56)  31.50 (29.93-33.06)  
Waist  cm 97.20 (95.41-98.99)  97.65 (96.68-98.62)  99.05 (97.69-100.40)  93.12 (88.91-97.33)  105.58 (103.75-107.42)  
HIP cm  105.29 (104.01-106.57)  104.07 (103.05-105.09)  104.38 (102.96-105.80)  98.35 (94.77-101.93)  105.44 (105.03-105.84)  
Waist-Hip Ratio 0.93 (0.92-0.94)  0.94 (0.93-0.95)  0.95 (0.94-0.96)  0.95 (0.93-0.98)  1.01 (0.99-1.03)  
BP Systole mmHg 124.54 (122.33-126.75)  123.58 (121.43-125.73)  126.74 (124.12-129.37)  126.32 (117.08-135.56)  129.56 (127.35-131.77)  
BP Diastole mmHg 80.00 (18.77-81.22)  77.87 (76.82-78.92) 79.33 (77.94-80.71)  77.29 (74.18-80.40)  81.13 (82.11-86.14)  
Total Serum 
Cholesterol  mmol/L 5.22 (5.08-5.37) 6.60 (6.31-6.89) 6.83  (6.58-7.09) 7.58  (7.25-7.90) 7.29  (6.79-7.79) 
Total Serum 
Triglyceride  mmol/L 1.69 (1.64-1.73) 1.71  (1.63-1.78) 1.73  (1.65-1.81) 2.06  (1.48-2.64) 2.15  (1.67-2.63) 
LDL mmol/L 3.26 (3.19-3.34) 3.18 (3.05-3.31) 3.19  (3.07-3.31) 3.26 (3.01-3.51) 3.27 (3.03-3.51) 
HDL mmol/L 1.01 (0.96-1.02) 0.89 (0.85-0.93) 0.86 (0.83-0.89) 0.78 (0.76-0.80) 0.79 (0.76-0.83) 
BMI: Body Mass Index, BP: Blood Pressure, CSME: Clinically Significant Macular Edema, FBG: Fasting Blood Glucose, DM: Diabetes Mellitus, 
DME: Diabetic Macular Edema, DR: Diabetic retinopathy, HbA1c: Glycosylated Hemoglobin, HDL: High Density Lipoprotein,  RBG: Random 
Blood Glucose, LDL: Low Denisty Lipoprotein 
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Table 6 Biochemical parameters (Mean & 95% CI) according to the presence of Diabetic Macular Edema and Clinically 
SIgnificant Macular Edema in patients with retinopathy (n=853) 
 No  DME (only DR) 
N=639 
DME (without CSME) 
N= 84 
CSME 
N=130  
FBG  mmol/L 7.09 (6.01-8.18)  9.13 (8.02-10.26)  10.07 (9.10-11.04) 
RBG  mmol/L 12.19 (10.12-13.26)  13.61 (11.47-15.75  14.97 (13.35-15.60)  
HbA1c  % 8.6 (7.1-9.0) 9.6  (9.2-9.9) 9.7  (9.3-10.1) 
DM Duration  Years 14.7  (11.5-18.3) 15.8 (14.7-16.9) 16.1  (14.8-18.7) 
Age  Years 52.1 (49.8-53.3) 53.7 (52.2-55.3) 53.6  (48.5-58.8) 
Urea mmol/L 10.26 (9.33-11.20)  11.58 (9.13-12.99)  10.98 (9.08-11.87)  
Creatinine µmol/L 75.05 (72.79-77.51)  75.80 (62.15-.57)  78.01 (71.60-85.78)  
Sodium mmol/L 141.02 (139.58-142.47) 141.61 (139.69-142.53) 141.33  (138.46-143.19) 
Potassium mmol/L  4.31 (4.04-4.73)  4.55 (4.44-4.66)  4.61  (4.32-4.85)  
Chloride  mmol/L 101.67 (100.99-104.04)  101.89 (100.57-102.64)  101.99  (100.39-102.58)  
BiCarbonate  mmol/L 24.08 (23.69-30.56)  24.22 (24.18-24.24)  23.88  (22.60-24.36)  
Urine Micro Albumin  µg/min 85.94 (70.23-98.64) 87.60 (68.77-101.42) 87.26 (71.51-104.82) 
Height  M 1.62 (1.61-1.63) 1.61 (1.58-1.71) 1.62 (1.59-1.64) 
Weight  Kg  72.32 (68.51-75.99)  71.44 (66.10-70.78)  75.52  (66.57-79.48)  
BMI  Kg/m2 27.53 (25.95-29.02)  28.01 (25.94-30.51)  28.57  (25.66-29.42)  
Waist Cm 99.01 (97.46-101.22)  100.15 (96.30-102.51)  100.64  (98.32-101.96)  
Hip  cm  104.11 (103.77-106.45) 104.44 (103.50-105.06) 104.17  (101.62-106.63) 
Waist-Hip Ratio  0.97 
(0.91-1.06) 
0.99 
(0.91-1.02) 
0.99 
(0.92-1.04) 
BP Systole mmHg 125 (124-126) 125 (122-128) 125  (122-129) 
BP Diastole mmHg 79  (76-80) 78  (75-81) 79  (77-81) 
Total Serum Cholesterol  mmol/L 6.22 (5.12-6.97) 6.62 (6.33-6.79) 6.86  (6.47-7.20) 
Total Serum Triglyceride  mmol/L 1.69 (1.64-1.74) 1.70  (1.63-1.78) 1.71  (1.64-1.78) 
LDL mmol/L 3.15 (3.10-3.21) 3.19 (3.15-3.23) 3.19  (3.07-3.31) 
HDL  mmol/L 0.98 (0.96-1.01) 0.88 (0.85-0.91) 0.85 (0.80-0.92) 
BMI: Body Mass Index, BP: Blood Pressure, CSME: Clinically Significant Macular Edema, FBG: Fasting Blood Glucose, DM: Diabetes Mellitus, 
DME: Diabetic Macular Edema, DR: Diabetic retinopathy, HbA1c: Glycosylated Hemoglobin, HDL: High Density Lipoprotein,  RBG: Random 
Blood Glucose, LDL: Low Denisty Lipoprotein 
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3.4 Factors associated with Diabetic Retinopathy and Diabetic Macular 
Edema 
Regarding the comparison of facors associated with DR, One Way ANOVA revealed 
statistically significant difference between the mean values of  FBG, RBG, HbA1c, Urinary 
Micro Albumin levels, Weight, BMI, Total Serum Cholesterol, Total Serum Triglycerides 
and HDL among No Diabetic Retinopathy, Mild NPDR, Moderate NPDR, Severe NPDR and 
PDR groups. The comparison of mean values and corresponding p-values are shown in table 
7.  
Post Hoc (Tukey’s) test revealed that mean value of FBG for No DR group was significantly 
less than mean FBG of all forms of DR.  
Mean HbA1c in patients with all forms of diabetic retinopathy (Mild NPDR, Moderate 
NPDR, Severe NPDR or PDR) was significantly greater than that in Patients without 
Retinopathy.  
There was no statistically significant difference found between the Mean Urinary Micro 
Albumin levels of patients without DR (No DR) group and that in Mild NPDR (=0.951) 
while it was significantly different from all other categories (p-values, 0.008 vs Moderate 
NPDR, 0.001 vs Severe NPDR and <0.001 vs PDR). Whereas, mean MICRAL level in 
patients with Mild NPDR was also found to be statistically significantly lesser than those in 
Moderate NPDR, Severe NPDR and PDR, p-values 0.046, 0.004, <0.001 respectively. 
Mean weight of patients with PDR (70.25 kg) was significantly more than the mean weight of 
patients without any retinopathy (81.14 Kg) p-value <0.001, or patients with Mild NPDR (. 
BMI, the mean BMI of patients with PDR (29.53 Kg/m2) was significantly greater than the 
mean BMI of patients without any retinopathy (26.53 kg/m2) p-value <0.001. Similarly, the 
patients with PDR had greater BMI compared to all other categories of DR (Mild NPDR 
26.57 Kg/m2, Moderate NPDR 26.57 Kg/m2, Severe NPDR 26.75 Kg/m2) with p-values 
<0.001, <0.001 and 0.004 respectively. 
Total Cholesterol was significantly lower than patients with No DR compared to patients 
with any form of Retinopathy, however there was no significant difference between different 
groups of DR.  
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Triglycerides in NO DR groups was significantly lower than those with Severe NPDR and 
PDR (p-values 0.031 and <0.001 respectively). Similarly triglyceride levels in PDR group 
was significantly more than all categories (No DR, Mild, Moderate and Severe NPDR) 
except Severe NPDR.HDL in No DR group was significantly higher than all categories of 
DR with p values <0.001 in all categories. 
Similarly for categorical variables pearson’s chi-squared test revealed that Hypertension and 
family history of CVD was more in patients with diabetic retinopathy of any form as 
compared to patients without DR  (p-value <0.001 and 0.004 respectively). No statistically 
significant difference was observed among the number of patients using Insulin across 
different grades of DR.   
Table 7 Variables with mean and 95% confidence intervales showing statistically significant difference across different 
grades of retinopathy (n=1167) 
Variables 
Mean (95%CI) 
No DR 
n=314 
Mild NPDR 
N=395  
Moderate NPDR 
n=321 
Severe NPDR 
n=45 
PDR 
n=92 
p-value* 
FBG  mmol/L 8.03 (7.70-8.37)  10.38 (9.94-10.82)  9.70 (9.10-10.31)  10.79 (9.71-11.86)  10.74 (9.64-11.83)  <0.001 
RBG  mmol/L 11.68 (11.10-12.26)  14.72 (14.16- 15.28)  13.97 (13.35-14.60)  14.62 (13.14-16.16)  15.66 (14.68-16.63) 0.01 
HbA1c  % 7.9  (7.6-8.2) 9.6  (9.2-9.9) 9.7  (9.3-10.1) 10.2  (9.4-10.7) 10.4  (9.5-11.4) <0.001 
DM Duration  Years 3.9  (3.5-4.3) 13.8 (12.7-14.9) 17.8  (16.8-18.7) 19.5  (15.9-22.9) 17.8  (15.6-20.0) <0.001 
Age  Years 51.1 (49.8-52.3) 53.7 (52.2-55.3) 50.6  (48.5-52.8) 53.9 (48.3-59.4) 54.7  (50.9-58.4) 0.045 
Urine Micro 
Albumin  µg/min 36.94 (32.23-41.64) 64.60 (48.77-80.42) 88.26 (70.60-105.91) 107.75 (63.23-152.27) 99.65 (60.28-139.03) <0.001 
Weight  Kg  70.25 (68.51-71.99)  68.44 (66.10-70.78)  69.52  (66.57-72.48)  66.33 (58.53-74.13)  81.14 (75.47-88.81)  0.01 
BMI  Kg/m2 26.53 (25.95-27.11)  26.57 (25.94-27.51)  26.57  (25.56-27.49)  26.75 (24.20-29.29)  29.53  (26.97-32.02)  0.02 
Waist cm 97.81 (96.36-99.27)  98.15 (96.30-100.01)  98.64  (96.32-100.96)  96.57 (87.82-105.31)  105.71  (101.58-
109.84)  
0.03 
HIP cm  105.13 (103.60-106.63) 104.49 (102.50-106.46) 104.13  (101.62-106.63-) 101.30 (94.07-108.53) 105.50  (99.14-111.85) 0.01 
Waist-Hip Ratio 0.93 
(0.92-0.94) 
0.95 
(0.93-0.97) 
0.95 
(0.93-0.97) 
0.96 
(0.92-1.00) 
1.01 
(0.71-1.31) 
0.01 
Total Serum 
Cholesterol mmol/L 5.22 (5.08-5.37) 6.60 (6.31-6.89) 6.83  (6.58-7.09) 7.58  (7.25-7.90) 7.29  (6.79-7.79) <0.001 
Total Serum 
Triglyceride  mmol/L 1.69 (1.64-1.73) 1.71  (1.63-1.78) 1.73  (1.65-1.81) 2.06  (1.48-2.64) 2.15  (1.67-2.63) <0.001 
HDL  mmol/L 1.01 (0.96-1.02) 0.89 (0.85-0.93) 0.86 (0.83-0.89) 0.78 (0.76-0.80) 0.79 (0.76-0.83) <0.001 
BMI: Body Mass Index, BP: Blood Pressure, CSME: Clinically Significant Macular Edema, FBG: Fasting Blood Glucose, DM: Diabetes Mellitus, 
DME: Diabetic Macular Edema, DR: Diabetic retinopathy, HbA1c: Glycosylated Hemoglobin, HDL: High Density Lipoprotein,  RBG: Random 
Blood Glucose, LDL: Low Denisty Lipoprotein *p-values were calculated using One-Way ANOVA 
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Similarly, regarding the factors associated with DME, One-Way ANOVA showed that mean 
values for FBG, HbA1c, Duration of diabetes, age, weight, BMI, waist, waist-hip ratio, total 
serum cholesterol and HDL were significantly different across the DR patients without DME, 
with DME and with CSME. The comparison of these variables with mean and 95% CIs and 
corresponding p-values are shown in table 8. 
Table 8 Variables with mean and 95% confidence intervales showing statistically significant difference according to 
presence of Diabetic Macular Edema 
 No  DME (only DR) 
N=639 
DME (without CSME) 
N= 84 
CSME 
N=130  
p-value* 
FBG  mmol/L 7.09 (6.01-8.18)  9.13 (8.02-10.26)  10.07 (9.10-11.04) 0.002 
HbA1c  % 8.6 (7.1-9.0) 9.6  (9.2-9.9) 9.7  (9.3-10.1) <0.001 
DM Duration  Years 14.7  (11.5-18.3) 15.8 (14.7-16.9) 16.1  (14.8-18.7) 0.012 
Age  Years 52.1 (49.8-53.3) 53.7 (52.2-55.3) 53.6  (48.5-58.8) 0.045 
Weight  Kg  72.32 (68.51-75.99)  71.44 (66.10-70.78)  75.52 (66.57-79.48)  0.018 
BMI  Kg/m2 27.53 (25.95-29.02)  28.01 (25.94-30.51)  28.57  (25.66-29.42)  0.029 
Waist  Cm 99.01 (97.46-101.22)  100.15 (96.30-102.51)  100.64  (98.32-101.96)  0.034 
Waist-Hip Ratio  0.97 
(0.91-1.06) 
0.99 
(0.91-1.02) 
0.99 
(0.92-1.04) 
0.017 
Total Serum Cholesterol  mmol/L 6.22 (5.12-6.97) 6.62 (6.33-6.79) 6.86  (6.47-7.20) 0.021 
HDL  mmol/L 0.98 (0.96-1.01) 0.88 (0.85-0.91) 0.85 (0.80-0.92) <0.001 
BMI: Body Mass Index, BP: Blood Pressure, CSME: Clinically Significant Macular Edema, FBG: Fasting Blood Glucose, DM: Diabetes Mellitus, 
DME: Diabetic Macular Edema, DR: Diabetic retinopathy, HbA1c: Glycosylated Hemoglobin, HDL: High Density Lipoprotein,  RBG: Random 
Blood Glucose, LDL: Low Denisty Lipoprotein 
*p-values were calculated using One Way ANOVA 
 
Chi-squared test revealed that only presence of hypertension significantly differed among 
groups of patients with DR only, with DME and wth CSME with p-value <0.001. 
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3.4.1 Univariate Analyses; Logistic Regression 
To see the association of variables showing significant diffeence in One-Way ANOVA and 
Chi-squared tests with DR, Unadjusted (Crude) Odds Ratios with corresponding 95% CIs 
were calculated for the variables showing statistically significant differences using Binary 
Logistic Regression for FBG, RBG, HbA1c, Duration of Diabetes, Age, Urinary Micro 
Albumin, Weight, BMI, Waist circumference, Hip circumference, Waist-Hip Ratio, Total 
Cholesterol, Triglycerides, HDL and presence of Hypertension. Table 9 shows the Crude 
Odds Ratios with corresponding 95% CIs for these variables. FBG, RBG, HbA1c, Duration 
of Diabetes, presence of Hypertension, BMI, HDL, Urinary Micro Albumin excretion, Waist 
and Waist Hip Ratio retained significant association with Diabetic Retinopathy. Whereas, 
Weight, Total Cholesterol, Triglyceride, Hip circumference and Age were unable to show 
significant association with DR. Table 9 shows Crude ORs with 95% CIs for these variables. 
Table 9 Univariate Analyses showing Crude Odds Ratios with 95% Conficence Intervales for the factors associated with 
Diabetic Retinopathy (n=1167)  No DR  
(n=314) 
DR 
(n=853)  
P-value  Crude OR  95% CI  
FBG <7 mmol/L >7 mmol/L  72 242  126 727  0.002   R 1.72  -- 1.34-2.95 RBG <11 mmol/L >11 mmol/L  85 229  138 715  0.048   R 1.92  -- 1.01-2.92 HbA1c < 7%  
≥7.1%  81 233  62 791  <0.001   R 4.43   -- 2.67-7.01 DM Duration <5 years > 5 years  222 92  316 537  <0.001   R 4.10   -- 3.02-5.79 HTN Absent Present  131 183  209 644  0.003   R 2.20   -- 1.89-2.57 BMI <30 kg/m2 >30 kg/m2  
 
232 
82 
 
421 
432 
 
<0.001  
 
R 
2.80  
 
-- 
1.04-8.51 HDL <1 mmol/L >1 mmol/L   188 126  643 210  <0.001   R 0.48   -- 0.03-0.89 Urinary Micro Albumin <100 mg/dl >100 mg/dl  140 174  24 829  <0.001   1.01   -- 1.01-1.02 Waist circumferencea <90 cm >90 cm  78 236  142 711  <0.001  1.64  -- 1.08-2.61 WHRb 
<0.95 >0.95  154 160  232 530  0.003  2.34  -- 1.00-4.70 a: IDF criteria, b: WHO criteria for WHR 
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Similarly, to calculate Unadjusted (Crude) Odds Ratios to see the association of FBG, HbA1c, 
Duration of Diabetes, Age, Weight, BMI, Total Cholesterol, HDL, Waist circumference, 
WHR and Hypertension with DME, Binary Logistic Regression revealed that only HbA1c, 
presence of Hypertension and HDL were significantly associated with DME while FBG,  
Duration of Diabetes, Age, BMI, Weight, Total Cholesterol, Waist & WHR failed to show 
any significant association. Table 10 shows the Crude ORs with 95% CIs for these variables.  
 
Table 10 Univariate Analyses showing Crude Odds Ratios with 95% Conficence Intervales for the factors associated with 
Diabetic Macular Edema (n=853)  No  DME 
N=639 
DME  
N= 214 
P-value  Crude OR  95% CI  
HbA1c < 7%  >7%  54 585  12 202  0.041  R 2.28  -- 1.58-6.07 HTN Absent Present  164 475  45 169  0.035  R 1.29  -- 1.12-3.45 HDL <1 mmol/L >1 mmol/L   483 156  160 54  0.021  R 0.79  -- 0.54-0.81 a: IDF criteria, cb: WHO criteria for WHR 
 
3.4.2 Multivariable Analyses: 
Multivariable Analyses by putting all significant variables from Univariate Analyses in single 
regression model showed that only FBG (Adjusted OR 1.02, 95% CI 1.01-1.03), HbA1c 
(Adjusted OR 2.20, 95%CI 1.36-3.54), Duration of diabetes (Adjusted OR 2.14, 95%CI 1.63-
2.81), presence of Hypertension (Adjusted OR 1.10, 95%CI 1.01-1.29) and Urinary Mircro 
Albumin excretion (Adjusted OR 1.02, 95%CI 1.01-1.03) were postively associated with any 
form of DR with Adjusted ORs.Whereas HDL was negatively associated with DR with 
Adjusted OR 0.85 and 95% CI 0.76-0.95.  
  
46 
 
Table 11 Multivariable Analyses showing Adjusted Odds Ratios with 95% Conficence Intervales for the factors associated 
with Diabetic Retinopathy (n=1167)  No DR (n=314) DR (n=853) p-value Adjusted OR 95% CI FBG* <6 mmol/L >6 mmol/L 72 242 126 727 0.04 R 1.02 -- 1.01-1.03 HbA1c * < 7%  
≥7.1% 81 233 62 791 <0.001 R 2.20 -- 1.36-3.54 DM Duration* <5 years > 5 years 222 92 316 537 <0.001 R 2.14 -- 1.63-2.81 HTN Absent Present 131 183 209 644 0.04 R 1.10 -- 1.01-1.29 Urinary Micro Albumin <100 mg/dl >100 mg/dl 
140 
174 
24 
829 
<0.001 R 
1.02 
-- 
1.01-1.03 
HDL <1 mmol/L >1 mmol/L  188 126 643 210  0.023 R 0.85 -- 0.76-0.95 
 
Moreover, for DME, multivariable analyses showed that out of 4 variables only HbA1c and 
Hypertension retained their association with DME with Adjusted ORs 1.87 (95% CI 1.06-
3.88) & 1.55 (95% CI 1.12-4.57) respectively. Table 12 shows the adjusted ORs with 95% CI 
for the factors associated with DME.  
Table 12 Multivariable Analyses showing Adjusted Odds Ratios with 95% Conficence Intervales for the factors associated 
with Diabetic Macular Edema (n=853) 
 No  DME 
N=639 
DME  
N= 214 
p-value Adjusted OR 95% CI 
HbA1c  
< 7%  
≥7.1% 
54 
585 
 
12 
202 
0.011 R 
1.87 
-- 
1.06-3.88 
HTN 
Absent 
Present 
164 
475 
45 
169 
0.042 R 
1.55 
1.12-4.57 
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Regarding the association of DME with different grades of DR, Severe NPDR was found to 
be positively associated with DME with OR 8.56 when compared with patients with Mild 
NPDR.Whereas,  the Odds of finding DME was 3 times more in patients with PDR compared 
to Mild NPDR. Table 13 shows the association of DME with different grades of retinopathy 
with corresponding ORs and 95%CI. 
Table 13 Association of DIabetic Macular Edema with different grades of retinopathy (n=853) 
 No  DME 
N=639 
DME  
N= 214 
p-value Odds Ratio 95% CI 
Mild NPDR 366 29 -- R -- 
Moderate NPDR 200 121 0.06 1.08 0.96-1.21 
Severe NPDR 15 30 <0.001 8.56 1.92-15.04 
PDR 58 34 0.014 3.02 1.22-5.03 
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Chapter 4: Discussion 
This study was conducted to examine the frequency of diabetic retinopathies using fundus 
photography as detection tool and factors associated with them in a tertiary care hospital in 
Karachi, Pakistan. To date, there are no studies published that used fundus photography to 
detect Diabetic Retinopathy (DR) and Diabetic Macular Edema (DME) as the primary tool in 
such patients in Pakistan. 
The population of interest was diabetic patients with either type 1 or 2 Diabetes Mellitus at 
the National Institute of Diabetes & Endocrinology, Dow University Hospital, Karachi 
Pakistan. These patients were referred to the department of Ophthalmology, in the same 
hospital for fundus photography between May 2010 and December 2013.  
We found a high frequency of DR (73.1%) among those who underwent fundus photography. 
This is more than the frequencies reported by previous studies from Pakistan and abroad. In a 
community based study by Mahar P.S. and associates [16] DR was found to be present in 
27.4% of diabetics. This study was however conducted in population based eye camps in 
Karachi. Moreover, a hospital based pilot study from the same city revealed a similar 26% 
frequency of DR among diabetics.[79]  
A study from India reported that 26.2% of the diabetic patients suffered from any form of 
retinopathy. [80] He B.B. and associates, in their study on Chinese patients, found that DR 
was present in 30% of the type 2 diabetics. [45] Similarly another study from Oman 
conducted on both T1DM & T2DM patients, reported DR prevalence to be 42.4%. [56]. 
Varma R. et al [57] & Tapp R.J. et al [44] reported DR prevalence to be 46% & 15.3% in US 
and Australian patients respectively.  
We found that the frequency of DR in our study was greater than all these national and 
international studies. The reason for this high frequency of DR can, firstly, be due to the use 
of highly sensitive fundus photography technique employed to diagnose DR. Secondly, we 
considered both T1DM & T2DM patients whereas all but one of these studies enrolled only 
T2DM patients. This might have an incremental effect on our findings as studies suggest that 
T1DM patients develop any form of DR earlier. Thirdly, our study was conducted in hospital 
setting, where the department of Ophthalmology and the National Institute of Diabetes and 
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Endocrinology are present in the same premises, which might have influenced only more 
severe cases of diabetes to be examined for fundus photography.   
Published literature from around the globe reports many factors associated with retinopathy 
among diabetics. Our study took into account the basic socio-demographic and biochemical 
factors and looked for their association with the presence of DR in both T1DM & T2DM 
patients. When these factors were taken individually, FBG, RBG, HbA1c, Duration of 
Diabetes, Presence of Hypertension, Weight, BMI, Total Cholesterol, Triglycerides, HDL 
Waist Circumference, Hip Circumference and Waist-Hip Ratio was found to be associated 
with DR. However, multivariable analyses to calculate adjusted ORs revealed only FBG 
(Adjusted OR 1.02; 95% CI, 1.01-1.03), HbA1c (Adjusted OR 2.20; 95% CI, 1.36-3.54), 
Duration of Diabetes (Adjusted OR 2.14; 95% CI, 1.63-2.81), Hypertension (Adjusted OR 
1.10; 95% CI, 1.01-1.29), Urinary Micro Albumin excretion (Adjusted OR 1.02; 95% CI, 
1.01-1.03) and HDL (Adjusted OR 0.85; 95% CI, 0.76-0.95 ) to be associated with DR. 
These findings are in accordance with the previously published national and international 
reports. 
We however, did not find any significant association with factors like BMI, WHR, Total 
Cholesterol with retinopathy among diabetics in the final regression model. This is in contrast 
to the findings of some researchers [29, 60, 62] 
Diabetic Macular Edema, which is considered further a complication of DR itself is often 
asymptomatic. Hence underestimation of the condition is always a possibility.  In our study, 
we found that Diabetic Macular Edema was present in 25.1% of patients with Diabetic 
Retinopathy. Whereas, CSME was present in atleast one eye in 15% of DR patients while 
11% of patients had CSME in both eyes.  To the best of our knowledge, only one study from 
Pakistan has reported the frequency of DME among diabetics. Qayyum A. et al [28] in their 
study from Quetta, Pakistan reports that DME was present in 33% of the patients with DR. 
likewise, in a study from USA, Lopes de Faria J.M. and associates [81]report that DME was 
present in 70% of the patients suffering from Diabetic Retinopathy.  
The relatively high frequency of CSME in these patients point towards the possible late 
acknowledgement of the condition and further exaggerated by poor risk factors control. 
50 
 
Regarding the factors associated with Diabetic Macular Edema, HbA1c, Hypertension and 
lower HDL values were independently associated. However, multivariable analyses to 
calculated adjusted ORs left only HbA1c (Adjusted OR 1.87; 95%CI, 1.06-3.88) and 
Hypertension (Adjusted OR 1.55; 95%CI, 1.12-4.57) to be positively associated with 
Diabetic Macular Edema. We also found that the Odds of finding DME in patients with 
Severe NPDR was 8.56 time more compared to Mild NPDR. Whereas the odds of finding 
DME in patients with PDR was 3 times more than in patients with Mild NPDR.  
No local study discussed the factors associated with DME. Lopez de Faria et al reported in 
their study that high BP, Presence of CVD and Proliferative Diabetic Retinopathy was 
positively associated with DME. [81] 
4.2 Strenghts 
This study used the gold standard procedure, fundus photography, for the detection of 
retinopathies among diabetic patients. It is also, to the best of our knowledge, the first study 
from Pakistan which studied the frequencies of Diabetic retinopathy and Diabetic Macular 
Edema and the factors associated with them in both type 1 and typ 2 diabetes mellitus 
patients. The study was conducted in a large tertiary care hospital in the city of Karachi 
which is the largest city of Pakistan with a multi-ethnic population of 20 Million people. 
Therefore, though the findings of this study cannot be generalized over the entire population 
of Pakistan, it points towards the national trends regarding the burden of and factors 
associated with Diabetic Retinopathy in Pakistan.  Furthermore, large sample size was 
included in the study to have optimal power for statistical analyses. Missing data was dealt 
with Multiple Imputations, an advanced and reliable statistical technique to avoid bias to the 
maximum. 
4.3 Limitations 
A number of limitations were present in the study. Firstly, retrospect ive analysis was done 
on the data which was clinically oriented and not specifically collected for research. Secondly, 
a possibility of overestimation of the frequency of DR cannot be ignored due to possible 
selection bias, as the fundus photography is an expensive procedure and usually more severe 
cases of diabetic patients are refered for it. Furthermore, high proportion of missing data 
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could be a source of bias even though missing values were imputed using statistical 
techniques.  
4.4 Implications 
The high frequency of DR & DME found in our study imply that there may be a general lack 
of appreciation of the risk factors associated with the complicatons of diabetes melilitus in the 
general population. Furthermore, general lack of data on DME suggests that in health care 
providers there might be a lack of acknowledgement of the sight threatening complication 
such as DME as a major health issue.  
4.5 Conclusion 
We observed a higher frequency of Diabetic Retinopathy and Diabetic Macular Edema with 
the use of undus photography as a detection tool compared to previous studies. Our findings 
suggest that poor glycemic control along with the presence of hypertension are the main 
roleplayers in the progression of retinopathies in diabetic patients.  
4.6 Recommendations 
Based on the findings of our research, strict glycemic control is warranted to apprehend the 
microvascular complications in the eye. Steps towards increasing awareness regarding risk 
factors and their prevention in diabetic patients is indicated. Moreover, further studies are 
recommended using cohort designs to quantify the risks of the factors associated with DR & 
DME.   
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